23andMe Investor Presentation Deck

'610 Primary Pharmacology* ● 23ME-00610 (¹610), a Fully Humanized, Effectorless IgG1, Inhibits Immunosuppressive Signaling via High Affinity Binding to CD200R1 Subnanomolar affinity Kills tumor cells in vitro • Anti-tumor activity in vivo Potential for monotherapy o activity on huPBMCs that do not respond to PD-1 antibody Potential for combination * PMID: 37288324 ¹610 Activates T-cell Function by Blocking the CD200R1 Checkpoint Tumor cell Tumor cell CD200 +23ME-00610 DOO CD290R1 T cell ↓ IFNY +1-2 Antitumor cytotoxicity Tcell tIFNy t12 Antitumor cytotoxicity *CD200-expressing cell types include tumor, stroma and endothelial IFN, interferon; IL, interleukin '610 Clinical Development* Well tolerated up to 1400 mg • PK supports Q3W (or better) Promising therapeutic index, projected dose ≥ ~600 mg • Monotherapy dev ongoing O Further expansion in NE and OC for safety, PK, PD and dose selection Indication CDPs and TPPS * Rasco, et al., 2023, SITC Annual Meeting #619; Glatt, et al., 2023 SITC Annual Meeting #609 Copyright © 2024 23and Me, Inc. 23andMe 24

View entire presentation